Advertisement
Australia markets close in 2 hours 53 minutes

  • ALL ORDS

    7,782.90
    -116.00 (-1.47%)
     

  • ASX 200

    7,532.90
    -109.20 (-1.43%)
     

  • AUD/USD

    0.6378
    -0.0047 (-0.74%)
     

  • OIL

    85.41
    +2.68 (+3.24%)
     

  • GOLD

    2,408.00
    +10.00 (+0.42%)
     

  • Bitcoin AUD

    96,767.79
    -509.73 (-0.52%)
     

  • CMC Crypto 200

    1,265.31
    +379.77 (+40.76%)
     

  • AUD/EUR

    0.6000
    -0.0031 (-0.52%)
     

  • AUD/NZD

    1.0869
    -0.0006 (-0.06%)
     

  • NZX 50

    11,745.74
    -90.30 (-0.76%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,058.66
    -327.21 (-2.00%)
     

  • NIKKEI 225

    36,818.81
    -1,260.89 (-3.31%)
     

Cue Biopharma, Inc. (CUE) Shares March Higher, Can It Continue?

Zacks Equity Research

As of late, it has definitely been a great time to be an investor inCue Biopharma, Inc. CUE. The stock has moved higher by 38% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider CUE’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as CUE has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. You can see the complete list of today’s Zacks #1 Rank stocks here.

Free: Zacks’ Single Best Stock Set to Double

Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

ADVERTISEMENT

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

See 5 Stocks Set to Double>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Cue Biopharma, Inc. (CUE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research